AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02856581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02856581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Complete counseling session
Study NCT02856581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Complete counseling session
Study NCT01215734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
Description: 0.5 ml of HD-TIV on visit 1
Study NCT01215734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Trivalent Inactivated Flu Vaccine
Description: Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
Study NCT01065636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Resistance Training
Description: Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
Study NCT01065636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Aerobic Training
Description: Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
Study NCT01065636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Resistance/Aerobic Exercise
Description: Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
Study NCT01912703 — intervention group
Intervention type: OTHER
Intervention: Telephone interview
Description: Subjects with incomplete data will be asked to complete a telephone interview
Study NCT03583762 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mass spectrometry
Description: Molecular diagnostic test for bacterial identification from bacterial colony
Study NCT03583762 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microarray assay
Description: Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
Study NCT04549597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Use of tenapanor
Study NCT01343134 — intervention group
Intervention type: DEVICE
Intervention: Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)
Description: Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
Study NCT02278848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
Description: Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
Study NCT02773017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine A
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study NCT02773017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine B
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study NCT02773017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine C
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study NCT02372019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBM With Active Fear Reactivation
Description: Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting.
Study NCT02372019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBM With Inert Fear Reactivation
Description: Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control.
Study NCT02372019 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inert CBM With Inert Fear Reactivation
Description: Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions.
Study NCT00665379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Compression therapy (Trico bandages)
Description: Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
Study NCT00665379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Compression therapy (C2L bandages)
Description: Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
Study NCT02756052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial direct-current stimulation
Description: NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
Study NCT02756052 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct-current stimulation
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
Study NCT00425620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SinuNase
Description: Lavage
Study NCT01523808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
Study NCT01876732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
Study NCT03441763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emed foot device
Description: foot pressure will be measure by using emed foot pressure system
Study NCT04879082 — intervention group
Intervention type: OTHER
Intervention: Professional course, occupational exposures
Description: The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past.
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Diclofenac Sodium
Description: 1% diclofenac sodium
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Diclofenac Sodium
Description: 1% diclofenac sodium
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Menthol
Description: 3% Menthol
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Menthol
Description: 3% Menthol
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.09% Menthol
Description: 0.09% Menthol
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.09% Menthol
Description: 0.09% Menthol
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.2% Sodium Lauryl Sulfate
Description: 0.2% Sodium Lauryl Sulfate
Study NCT02169154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline
Study NCT00800163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED Activation/Immediate Transfer
Description: ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
Study NCT04292093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home rehabilitation training
Description: The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
Study NCT03293277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: Intranasal Dexmedetomidine
Study NCT04292093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home control activity
Description: The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
Study NCT02675348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Beef Protein
Description: Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
Study NCT02675348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: whey Protein
Description: Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
Study NCT02675348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: CHO
Description: Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
Study NCT04203329 — intervention group
Intervention type: DEVICE
Intervention: Femoral Venous Vascular Closure
Description: Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
Study NCT04569318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Beam
Description: One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
Study NCT03974191 — intervention group
Intervention type: OTHER
Intervention: Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.
Description: 13-year prospective longitudinal cohort study
Study NCT03274596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Study NCT03274596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pp-TMS assessment
Description: SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
Study NCT02559518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pp-TMS assessment
Description: SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
Study NCT02899585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study NCT02899585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Score
Study NCT01018524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall reconstruction
Description: suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
Study NCT00574743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated Mycophenolate Sodium
Study NCT00762099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pre-operative dose 150 mg Post-operative dose 75 mg BID
Study NCT00762099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/sugar tabs will look identical to active drug.
Study NCT01456936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Triple dummy placebo for each treatment arm
Study NCT01456936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline tartrate
Description: Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
Study NCT01456936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion hydrochloride
Description: Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
Study NCT01456936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Patch
Description: Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
Study NCT01927965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide™ 001
Description: Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
Study NCT01607177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily text message reminders
Description: Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
Study NCT03462836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ketamine/lidocaine/IV PCA apply
Description: In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
Study NCT03462836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA only apply
Description: IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
Study NCT02654587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSE2101